FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance

Lung cancer has high morbidity and mortality rates worldwide, and NSCLC accounts for 85% of all lung cancer cases. Despite the development of targeted therapies and immunotherapy, many NSCLC patients do not effectively respond to treatment, and new treatment strategies are urgently needed. Aberrant...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Feng, Zhu, Xinhai, Niu, Yuchun, Nai, Aitao, Bashir, Shoaib, Xiong, Yan, Dong, Yunlong, Li, Yin, Song, Jian, Xu, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950728/
https://www.ncbi.nlm.nih.gov/pubmed/36845692
http://dx.doi.org/10.3389/fonc.2023.1088444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950728/
https://www.ncbi.nlm.nih.gov/pubmed/36845692
http://dx.doi.org/10.3389/fonc.2023.1088444

Ejemplares similares